I think they are the company to watch, but I guess I mean this from a scientific point of view. I am not planning on loading up as soon as they go public.
Still, it was my impression that they raised millions (or hunderds of millions) as a private company, and money talks...
Still, I will be waiting on the sidelines mainly because I want to see how well RNAi can be delivered as a drug. As a research tool, it is great, but that's not enough to make a profitable public company.
[ALNY’s CEO and some of his lieutenants are former MLNM people. The new hire, in addition to having worked at MLNM, was Celera’s chief patent counsel for three years.]
>> Alnylam Pharmaceuticals Appoints Robert Millman as Chief Patent Counsel
CAMBRIDGE, Mass., Sept. 13 /PRNewswire-FirstCall/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), the leading therapeutic RNA interference (RNAi) company, today announced the appointment of Robert Millman as Chief Patent Counsel. Mr. Millman has over 25 years of experience in the biotechnology sector, and he has served as a consultant for Alnylam since June 2003.
In his position at Alnylam, Mr. Millman will be responsible for directing all aspects of the company's intellectual property activities, and will be a member of the company's management team.
"We are delighted to formally welcome Robert to our team," commented Barry Greene, Chief Operating Officer of Alnylam. "He has demonstrated leadership and keen insight in shaping our significant IP estate for RNAi therapeutics, and his wealth of experience in developing and executing IP strategy will be invaluable as we continue to strengthen and build our patent position."
Mr. Millman has over 15 years of experience creating and managing intellectual property and patent estates for biotechnology companies. Most recently, he was a freelance intellectual property consultant for biotechnology companies and served as the Interim Chief Patent Counsel at Infinity Pharmaceuticals, Inc. From 1999 to 2002, Mr. Millman was Chief IP Counsel at Celera Genomics, where he oversaw the development and implementation of IP protection plans to secure asset value. Previously, Mr. Millman served as Patent Counsel at Millennium Pharmaceuticals, Inc. Earlier in his career, he held an associate position at Morrison and Foerster LLP. Mr. Millman received his J.D. degree from the Washington College of Law at The American University. He obtained an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside.
"I am extremely excited to be working in the field of RNAi, an area where intellectual property will be an important component of the business strategy, and I look forward to working with the management team to build on Alnylam's strong foundation in RNAi," stated Mr. Millman. "I have been impressed with the company's commitment to build a pipeline of RNAi therapeutics and their business strategy aimed at creating value from their intellectual property estate." <<
Market Data 
Markets 
AI
